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Glycerol mycolates from synthetic mycolic acids 
Omar T. Ali, Mohaned M. Sahb, Juma’a R. Al Dulayymi and Mark S. Baird, 
School of Chemistry, Bangor University, Bangor, Gwynedd, Wales, UK LL57 2UW 
Abstract: R- and S-Glycerol mycolates derived from single synthetic α-, keto- and 
methoxy-mycolic acids, such as compound A are described. 
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1. Introduction
Complex mixtures of  mycolic acids are characteristic components of  mycobacterial cells, 
either bound to the wall as arabinose esters or  not bound to the wall, as free acids or 
esterified to sugars such as glucose (GMM), or trehalose (dimycolate, TDM; monomycolate, 
TMM) [1].  As early as 1956, it was shown that Mycobacterium tuberculosis contains 
mycoloylglycerols (ca. 90 carbons) [2 - 5]. Glycerol monomycolate (GroMM, also known as 
MMG) is also present in the wax C fraction of BCG [6]. Shorter chain glycerol esters were 
isolated from Nocardia rhodochrous, which contains nocardomycoloylglycerols (40 – 44 
carbons)  [7], from Corynebacterium pseudotuberculosis (30 – 36 carbons) [8], from 
Nocardia asteroides (50 – 56 carbons) [9], and from Rhodococcus lentifragmentus (32 – 50 
carbons) [10].  
The glycerol is esterified at one of the primary alcohol groups [11]. The antigen isolated from 
Mycobacterium bovis BCG was shown to exist as two stereoisomers at the glycerol by 
comparison of the NMR spectrum with those of R- and S-glycerol isomers of GroMM 
prepared from mycolic acid mixtures isolated from M.tuberculosis H37Rv cells [12]. Both 
semi-synthetic GroMMs stimulate CD-1 restricted T cell clones, the R-isomer being more 
slightly more stimulatory than GroMM from Mycobacterium bovis BCG, the S-isomer 
slightly less stimulatory. In this system, R and S-isomers of GroMM prepared from a 32 
carbon corynomycolate almost completely removed the stimulatory effect, in line with earlier 
results [13]. The secondary alcohol group of the glycerol was also necessary for activity. 
GroMM was presented by M. tuberculosis infected dendritic cells, demonstrating that the 
antigen is available for presentation during natural infection. Ex vivo experiments showed 
that GroMM stimulated T cells from vaccinated or latently infected healthy donors but not 
those from patients with active tuberculosis, suggesting that GroMM-specific T cells are 
primed during infection and their detection correlates with lack of clinically active disease 
[12]. Hattori et al. immunized guinea pigs with bacillus Calmette–Guérin (BCG) expressing 
high levels of GroMM and then monitored skin reactions at the site of inoculation with 
GroMM-containing liposome. The host responses to GroMM produced by dormant 
mycobacteria contribute to their long-term survival in the host [14], again identifying GroMM 
M
AN
UC
RI
PT
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  
 
• 2 
 
as potentially associated with latent infection.  GroMM is a ligand for the human, but not 
mouse macrophage inducible c-type lectin, Mincle [15], the signalling process being 
dependent on structure [16, 17].   
A 32 carbon monomycolyl GroMM analogue demonstrated enhanced immunostimulatory 
activity in a dioctadecyl ammonium bromide/Ag85B-ESAT-6 formulation. Elevated levels of 
IFN-gamma and IL-6 were produced in spleen cells from mice immunised with a 32 carbon 
GroMM analogue comparable activity to the potent Th1 adjuvant, trehalose 6,6'-dibehenate 
[18 – 22].  Interest in the properties and applications of GroMMs therefore remains high [23 - 
26]. 
 
Derivatives of GroMMs in which the two other glycerol alcohol groups are acylated have 
also been reported [27]. 
 
Layre et al. prepared GroMM using potassium salts of mixtures of mycolates isolated from 
M. tuberculosis H37Rv [12], using (S)- and (R)-isopropylidene-glycerol p-toluenesulfonates 
1 and 2 (Scheme 1).    
 
Scheme 1: The synthesis of GroMM with natural mycolic acid [13] 
Nordly et al. synthesised GroMMs from unfunctionalised C32 β-hydroxy acids producing a 
mixture of four stereoisomers, and carried out extensive studies of their bioactivity [21].   
In order to determine whether the detailed structure of the individual mycolic acid in the 
natural mixtures leads to changes in their biological properties, or whether the activity is 
dominated by the glycerol fragment, we now report the synthesis of GroMMs based on 
coupling of a set of individual complete synthetic mycolic acids, taken from various Mtb 
classes, with both glycerol stereoisomers. 
. 
2. Results and discussion 
The synthetic mycolic esters of R-glycerol 10 were prepared by two methods. In the first, the 
TBDMS protected MA was coupled with acetonide 8 promoted by DCC and DMAP. In the 
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second, the unprotected acid was coupled with tosylate 2 in the presence of cesium hydrogen 
carbonate. (Scheme 2) 
 
Scheme 2: (i) DMAP, DCC; (ii) TFA, CH2Cl2; (iii) CsHCO3; (iv) HCl, THF, H2O 
 
Table 1: Synthetic mycolates of R-glycerol 
Mycolic acid                  
R’’ Number Method Yield 9/12 
(%) 
Yield 10 (%) 
OH
OTBDMSO
(CH2)23CH3
(CH2)16 (CH2)17
CH3(CH2)17
OMe
 
TBDMS 7a 1 9a (72) 10a (86) 
 
H 11b 2 12b (85) 10b (86) 
 
H 11c 2 12c (50) 10c (88) 
 
H 11d 2 12d (85) 10d (87) 
 
The S-glycerol mycolate esters were prepared by a modified method in which the glycerol 
was protected by benzyl groups, which, after coupling, were removed by hydrogenolysis:  
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Scheme 3: (i) TsCl, py; (ii) RCOOH, CsHCO3; (iii) Pd(OH)2, H2, CH2Cl2, MeOH 
 
Table 3. Synthetic mycolates of S-glycerol 
Mycolic acid  RCOOH         Number Yield 15 Yield 16 
 
11b 15b (71) 16b (92) 
 
11c 15c (62) 16c (85) 
 
11e 15e (58)  16e (74) 
 
11f 15f (72) 16f (92) 
 
11g 15g (59) 16g (87) 
 
1. Conclusion  
A set of nine R- and S-glycerol mycolates derived from single synthetic α-, keto- and 
methoxy-mycolic acids are described. The GroMMs 10a – 10d did not show any significant 
effects in the stimulation of cytokines in bone marrow dendritic cells (BMDCs) [28], unlike 
related TDMs and TMMs, GMMs and arabinose mycolates which activate BMDCs in terms 
of production of pro-inflammatory cytokines (IL-6 and TNF-α) and reactive oxygen species, 
upregulation of costimulatory molecules and activation of NLRP3 inflammasome by a 
mechanism dependent on Mincle [29]. However, they do show strong and selective effects in 
the stimulation of CD1b-restricted GEM T cell responses, mirroring the effects of the 
corresponding free mycolic acids [30].   
 
2. Experimental:  
2.1 General considerations 
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All chemicals were purchased from commercial suppliers. THF was distilled over sodium 
and benzophenone under nitrogen, while dichloromethane was distilled over calcium hydride. 
Petrol refers to the fraction b.p. 40–60 °C. Organic solutions were dried over anhydrous 
magnesium sulfate. Reactions carried out under inert conditions were under a slow stream of 
nitrogen. Column chromatography and thin layer chromatography were carried out using 
Silica gel (Merck 7736, 40 – 63 micron) and silica gel plates (Merck, 60F254). Rf values for 
the final GroMMs
 
were all in the range  0.31 – 0.39 using 20:1 chloroform/methanol.
 
Infra-
red (IR) spectra were carried out on a Perkin-Elmer 1600 F.T.I.R. spectrometer as films or 
KBr discs or directly on a Bruker ALPHA FTIR spectrometer. Optical rotations were 
measured as solutions in chloroform using a Polar 2001 automatic polarimeter. NMR spectra 
were recorded either on an Advance 400 or 500 spectrometers. Spectra are reproduced in the 
Supplementary Information. Mass spectra were recorded on a Bruker matrix-assisted laser 
desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS)  values are given 
plus sodium to an accuracy of 1 d.p. Accurate mass data were run by Dr Paul Gates (Bristol 
University) or the EPSRC UK National Mass Spectrometry Facility at Swansea University.  
  
4.2 ((R)-2,3-Dihydroxypropyl (R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl)cyclopropyl)octadecyl)hexacosanoate (10a)  
(a) (R)-2-((R)-1-((tert-Butyldimethylsilyl)oxy)-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl)cyclopropyl)octadecyl)hexacosanoic acid (7a) [31] (90 mg, 0.06 mmol) 
and DMAP (10 mg, 0.08 mmol) were added to a stirred solution of (S)-(2,2-dimethyl-1,3-
dioxolan-4-yl)methanol [32] (10 mg, 0.07 mmol) in CH2Cl2 (2 mL). A solution of DCC (20 
mg; 0.09 mmol) in CH2Cl2 (2 mL) was added dropwise with stirring under nitrogen over 120 
min then stirred for 1 h at room temperature. Precipitated dicyclohexyl urea was filtered off 
and washed with dichloromethane (10 mL). The solvent was evaporated and the crude 
product was purified by column chromatography eluting with petrol/ethyl acetate (20:1) to 
give a semi-solid, compound 9a (70 mg, 72%), 	 − 6.7 (c 1.4, CHCl3), [Found (M+Na)+: 
1505.5, C97H192NaO6Si requires: 1504.4], which showed δH (500 MHz, CDCl3): 4.33 – 4.26 
(1H, m), 4.11 (1H, dd, J 2.4, 5.4 Hz), 4.06 (1H, dd, J 6.4, 8.4 Hz), 3.94 – 3.87 (1H, m), 3.75 
(1H, dd, J 6.0, 8.4 Hz), 3.34 (3H, s), 3.24 – 3.15 (1H, m), 2.98 – 2.92 (1H, m), 2.55 (1H, ddd, 
J 3.8, 6.9, 10.8 Hz), 2.00 – 1.01 ((153H, m including two singlets at 1.43 (3H, s) and 1.36 
(3H, s)), 0.91 – 0.83 (18H, including d for the methyl group (J 7 Hz) and a t (J 6.8 Hz) for the 
terminal methyl group and s for the tert-butyl group), 0.69 – 0.61 (2H, m), 0.56 (1H, dt, J 3.7, 
7.6 Hz), 0.04 (3H, s), 0.01 (3H, s), -0.34 (1H, q, J 5.2 Hz); δC (126 MHz, CDCl3): 174.7, 
109.8, 85.6, 73.7, 66.8, 64.4, 57.9, 55.9, 51.6, 35.5, 35.1, 34.0, 32.6, 32.1, 30.7, 30.4, 30.2, 
30.1, 29.9, 29.8, 29.6, 29.5, 28.9, 28.0, 27.7, 26.9, 26.3, 26.2, 25.9, 25.6, 25.5, 24.9, 24.1, 
22.9, 18.1, 15.9, 15.0, 14.3, 11.1, -4.2, -4.7; νmax/cm-1: 2918, 2849, 1726, 1465, 1256, 1178.. 
(b)Trifluoroacetic acid in dichloromethane (1:1, 0.4 mL) was added to a stirred solution of  
ester (9a) (50 mg, 0.03 mmol) in CH2Cl2 (2 mL) at 0 °C. The solution was stirred at 0 °C for 
12 h, when TLC showed no starting material was left and the reaction mixture was worked up 
by quenching with sat. aq. NaHCO3 (20 mL) and the product was extracted with CH2Cl2 (2 × 
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10 mL) and the combined organic layers were dried and evaporated. The crude product was 
purified by column chromatography eluting with chloroform/methanol (15:1) to give a semi-
solid, the title compound (10a) (40 mg, 86%), 	 − 8.4 (c 1.1, CHCl3), [MALDI-Found 
(M+Na)+: 1350.3199, C88H174NaO6 requires: 1350.3203], which showed δH (500 MHz, 
C6D6): 4.25 (1H, dd, J 6.6, 11.4, Hz), 4.12 (1H, dd, J 3.9, 11.4, Hz), 3.81 – 3.71 (2H, m), 3.47 
(1H, dd, J 4.2, 11.3, Hz), 3.40 (1H, dd, J 5.5, 11.4, Hz), 3.27 (3H, s), 3.03 – 2.97 (1H, m), 
2.55 (1H, dd, J 9.0, 12.5, Hz), 1.9-1.25 (149H, m), 1.00 (3H, d, J 6.8 Hz), 0.93 (7H, including 
t, J 6.6 Hz), 0.78 – 0.71 (2H, m), 0.68 (1H, dt, J 3.7, 7.6 Hz), -0.01 (1H, q, J  5.0 Hz); δC (126 
MHz, C6D6): 175.2, 85.4, 73.2, 70.4, 65.5, 63.6, 57.6, 53.0, 35.9, 35.8, 33.0, 32.4, 30.9, 30.8, 
30.6, 30.5, 30.3, 30.2, 30.1, 30.0, 29.9, 29.8, 29.3, 28.2, 28.0, 26.7, 26.0, 23.1, 16.3, 15.3, 
14.4, 11.5; νmax/cm-1: 3499  2928, 2854, 1744, 1435, 1267, 1178. 
 
4.3 (R)-2,3-Dihydroxypropyl (R)-2-((R)-1-hydroxy-12-((1R,2S)-2-(14-((1R,2S)-2-eicosyl-
cyclopropyl)tetradecyl)cyclopropyl)dodecyl) hexacosanoate (10b) 
(a) Dry cesium hydrogen carbonate (120 mg, 0.33 mmol) was added to a stirred solution of   
acid (11b) [33] (70 mg, 0.06 mmol) in a mixture of THF:DMF (1:1, 4 mL) at room 
temperature. The mixture was left at room temperature for 1 h then (R)-(2,2-dimethyl-1,3-
dioxolan-4-yl)methyl 4-methylbenzenesulfonate 2 [34] (40 mg, 0.13 mmol) was added. The 
mixture was brought to 70 °C and left at this temperature for 18 h, then cooled to room 
temperature and diluted with ethyl acetate (15 mL). The organic layer washed twice with 
water, dried and concentrated. Column chromatography eluting with petrol/ethyl acetate (5:1) 
gave a semi-solid,  title compound (12b) (66 mg, 85%), 	 − 4.7 (c 1.2, CHCl3), [Found 
(M+Na)+: 1274.2, C84H162O5Na requires: 1274.2]. This showed δH (400 MHz, CDCl3): 4.27 – 
4.20 (1H, m), 4.10 (1H, dd, J 3.3, 9.9 Hz), 4.06 (1H, dd, J 4.3, 9.9 Hz), 3.97 (1H, dd, J 6.5, 
8.5 Hz), 3.65 (1H, dd, J 5.9, 8.5 Hz), 3.56 (1H, br s), 2.41 – 2.28 (2H, m), 1.38 – 0.98 
((140H, m including 1.34 (3H, s), 1.26 (3H, s)), 0.78 (6H, t, J 6.8), 0.61 – 0.50 (4H, m), 0.50 
– 0.41 (2H, m), -0.43 (2H, q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.3, 109.8, 73.4, 72.3, 66.3, 
64.4, 51.3, 35.6, 31.9, 30.2, 29.73, 29.7, 29.6, 29.5, 29.4, 28.7, 27.4, 26.7, 25.7, 25.3, 22.7, 
15.7, 14.1, 10.9; νmax/ cm-1: 3430, 3011, 2925, 2886,1744, 1232, 759, 669. 
(b) Hydrochloric acid (2 M, 0.04 mL) was added to a stirred solution of  ester (12b) (55 mg, 
0.04 mmol) in THF (25 mL) at room temperature, then stirred at 40 °C for 16 h. The mixture 
was quenched at room temperature with sat. aq. NaHCO3 (10 mL), the product was extracted 
with CH2Cl2 (25 mL) and the aqueous phase was re-extracted with CH2Cl2 (3 × 25). The 
organic extracts were dried and concentrated. The crude residue was purified by column 
chromatography eluting with petrol/ethyl acetate (4:1) to give a semi-solid, the title 
compound (10b) (46 mg, 86%), 	 − 6.5 (c 0.90, CHCl3) [MALDI-Found (M+Na)+: 
1234.2005, C81H158NaO5 requires: 1234.2001], which showed δH (400 MHz, CDCl3): 4.30 – 
4.26 (2H, m), 4.01 – 3.95 (1H, m), 3.76 – 3.61 (3H, m), 2.54 – 2.44 (1H, m), 1.49 – 1.08 
(137H, m), 0.90 (6H, t, J 6.8 Hz), 0.71 – 0.63 (4H, m), 0.58 (2H, dt, J 3.7, 7.6 Hz), -0.31 (2H, 
q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.6, 73.1, 70.1, 65.4, 63.4, 52.3, 35.5, 32.1, 30.4, 29.9, 
29.8, 29.7, 29.6, 29.5, 29.5, 28.9, 27.6, 25.6, 22.8, 15.9, 14.3, 11.1; νmax/cm-1: 3430, 3011, 
2925, 2886,1744, 1232, 759, 669. 
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4.4 (R)-2,3-Dihydroxypropyl (R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-
18-methylhexatriacontyl)cyclopropyl)octadecyl)tetracosanoate (10c) 
 (a) Dry cesium hydrogen carbonate (100 mg, 0.40 mmol) was added to a stirred solution of   
acid (11c) [36] (70 mg, 0.05 mmol) in a mixture of THF:DMF (1:1, 2 mL) at room 
temperature. The mixture was left at room temperature for 1 h then (R)-tosylate (2) (80 mg, 
0.2 mmol) was added. The mixture was heated  at 70 °C for 18 h, then worked up and 
purified as before to give a semi-solid, compound (12c) (70 mg, 50%), 	 − 6.2 (c 0.90, 
CHCl3) [Found (M+Na)+: 1362.5, C89H174NaO6 requires: 1362.3]; δH (400 MHz, CDCl3): 
4.37 – 4.29 (1H, m), 4.20 (1H, dd, J 3.3, 9.9 Hz), 4.16 (1H, dd, J 2.4, 8.0 Hz), 4.07 (1H, dd, J 
6.5, 8.5 Hz), 3.75 (1H, dd, J 5.9, 8.4 Hz), 3.66 (1H, br s), 3.34 (3H, s), 2.99 – 2.92 (1H, m), 
2.52 – 2.37 (2H, m), 1.48 – 1.06 ((149H, m including 1.44 (3H, s), 1.36 (3H, s)), 0.88 (6H, t, 
J 6.8 Hz), 0.85 (3H, d, J 6.9 Hz), 0.64 (2H, br s), 0.60 – 0.51 (1H, m), -0.34 (1H, q, J 5.3 Hz); 
δC (101 MHz, CDCl3): 175.3, 109.8, 85.5, 73.4, 72.3, 66.3, 64.4, 57.7, 51.3, 35.5, 35.3, 32.4, 
31.9, 30.8, 30.2, 30.0, 29.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.7, 27.6, 27.4, 26.7, 26.1, 25.7, 
25.3, 22.7, 15.8, 14.9, 14.1, 10.9; νmax/ cm-1: 3511, 2918, 2849, 1726, 1465, 1256, 1178.  
(b) Hydrochloric acid (2 M, 0.04 mL) was added with stirring to ester (12c) (65 mg, 
0.05mmol) in THF (34 ml) at room temperature. The mixture was stirred at 40 °C for 16 h, 
then worked up and purified as before to give a semi-solid, the title compound (10c) (56 mg, 
88%), 	 − 9.3 (c 1.2, CHCl3) [MALDI-Found (M+Na)+: 1322.2880, C86H170NaO6 
requires: 1322.2890]; δH (500 MHz, CDCl3): 4.30 – 4.22 (2H, m), 3.99 – 3.92 (1H, m), 3.74 – 
3.67 (2H, m), 3.62 (1H, dd, J 5.5, 11.4 Hz), 3.34 (3H, s), 2.98 – 2.92 (1H, m), 2.50 – 2.42 
(1H, m), 1.74 – 1.01 (146 H, m), 0.88 (6H, t, J 6.9 Hz), 0.84 (3H, d, J 6.9 Hz), 0.69 – 0.60 
(2H, m), 0.55 (1H, dt, J 3.9, 8.4 Hz), -0.34 (1H, q, J 5.1 Hz); δC (101 MHz, CDCl3): 175.6, 
85.6, 73.1, 70.1, 65.4, 63.4, 57.9, 52.3, 35.5, 35.4, 34.1, 32.5, 32.1, 30.6, 30.4, 30.1, 30.0, 
29.9, 29.8, 29.7, 29.6, 29.5, 28.9, 27.7, 27.6, 26.3, 25.6, 25.1, 22.8, 15.9, 15.0, 14.3, 11.1; 
νmax/cm-1: 3511, 2918, 2849, 1726, 1465, 1256, 1178.  
 
4.5 (R)-2,3-Dihydroxypropyl (2R)-2-((1R)-1-hydroxy-16-((1R,2S)-2-(20-methyl-19-oxo-
octatriacontyl)cyclopropyl)hexadecyl)tetracosanoate (10d) 
 (a) Dry cesium hydrogen carbonate (110 mg, 0.50 mmol) was added to a stirred solution of  
acid (11d) [36] (80 mg, 0.06 mmol) in a mixture of THF:DMF (1:1, 3 mL) at room 
temperature. The mixture was stirred for 1 h then R-tosylate (2) (40 mg, 0.13 mmol) was 
added .The mixture was brought to 70 °C and left at this temperature for 18 h, then worked up 
and purified as before to give a semi-solid, compound (12d) (64 mg, 85%), 	 − 8.1 (c 
1.4, CHCl3) [Found (M+Na)+: 1346.9, C88H170NaO6 requires: 1346.3], which showed δH (400 
MHz, CDCl3): 4.40 – 4.32 (1H, m), 4.26 (1H, dd, J 5.9, 11.4 Hz), 4.20 (1H, dd, J 2.2, 5.4 
Hz), 4.14 (1H, dd, J 4.6, 11.4 Hz), 4.12 – 4.07 (1H, m), 3.78 (1H, ddd, J 2.3, 5.7, 8.3 Hz), 
3.73 – 3.65 (1H, m), 2.57 – 2.40 (4H, m), 1.66 – 1.11 ((146H, m including 1.46 (3H, s), 1.38 
(3H, s)), 1.07 (3H, d, J 6.9 Hz), 0.90 (6H, t, J 6.8 Hz), 0.71 – 0.63 (2H, m), 0.62 – 0.54 (1H, 
m), -0.31 (1H, q, J 5.2 Hz); δC (101 MHz, CDCl3): 215.2, 175.3, 109.8, 73.5, 72.3, 66.2, 64.6, 
51.5, 46.3, 41.1, 35.6, 35.5, 33.0, 31.9, 30.2, 29.7, 29.59, 29.5, 29.3, 28.7, 27.3, 26.7, 25.3, 
23.7, 22.7, 16.3, 15.7, 14.1, 10.9; νmax/ cm-1: 3455, 2944, 2861, 1722, 1146, 1382, 1214, 
1022. 
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(b) Hydrochloric acid (2 M, 0.04 mL) was added to a stirred solution of ester (12d) (60 mg, 
0.04 mmol) in THF (30 mL) at room temperature. The mixture was stirred was at 40 °C for 
16 h. then worked up and purified as before to give a semi-solid, the title compound (10d) 
(51 mg, 87%), 	 − 12 (c 1.1, CHCl3) [MALDI-Found (M+Na)+: 1306.2569, 
C85H166NaO6 requires: 1306.2577], which showed  δH (400 MHz, CDCl3): 4.30 (1H, dd, J 
4.1, 11.8 Hz), 4.25 (1H, dd, J 6.7, 11.8 Hz), 4.03 – 3.94 (1H, m), 3.77 – 3.70 (2H, m), 3.65 
(1H, dd, J 4.6, 10.5 Hz), 2.57 – 2.39 (4H, m), 1.76 – 1.10 (143H, m), 1.07 (3H, d, J 6.9 Hz), 
0.90 (6H, t, J 6.8 Hz), 0.66 (2H, br s), 0.58 (1H, dt, J 3.7, 7.8 Hz), -0.31 (1H, q, J 5.2 Hz); δC 
(101 MHz, CDCl3): 215.3, 175.4, 72.9, 69.7, 65.2, 63.3, 52.2, 46.3, 41.1, 37.9, 35.3, 33.0, 
31.9, 30.2, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.7, 27.4, 27.3, 25.5, 23.7, 22.7, 16.3, 15.8, 
14.1, 10.9; νmax/cm-1: 3455, 2944, 2861, 1722, 1146, 1382, 1214, 1022. 
4.6 (S)-2,3-Bis(benzyloxy)propyl alkanoate (15): General procedure 
Cesium hydrogen carbonate was added to a stirred solution of 1-O-p-toluene-sulfonyl-(S)-
2,3-di-O-benzylglycerol (14) [37], and acid in dry DMF:THF (1:5, 2 mL) at room 
temperature. The mixture was stirred at 70 ºC for 2 days, then diluted with ethyl acetate (10 
mL) and water (10 mL). The organic layer was separated and the aqueous layer was re-
extracted with ethyl acetate (3×10 mL). The combined organic layers were washed 
successively with water (15 mL) and brine (15 mL), dried and evaporated. The residue was 
purified by column chromatography. 
4.7 (S)-2,3-Dihydroxypropyl alkanoate (16): General procedure  
Palladium hydroxide on activated charcoal (20% Pd, 0.15 fold by weight) was stirred with 
compounds (15) in dry CH2Cl2 : MeOH (1:1, 2 mL) at room temperature under hydrogen. 
The mixture was stirred for 24 h then filtered through celite. The celite was washed with 
CH2Cl2 (10 mL), the filtrate was evaporated, and the residue purified by column 
chromatography. 
 
4.8 (S)-2,3-Dihydroxypropyl (2R)-2-(1-hydroxy-12-((1R,2S)-2-(14-((2S)-2-eicosylcyclo-
propyl)tetradecyl)cyclopropyl)dodecyl)hexacosanoate (16b) 
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(a) Cesium hydrogen carbonate (0.0616 g, 0.317 mmol), tosylate (14) (0.0298 g, 0.0698 
mmol) and the acid (11b) [33] (0.0724 g, 0.0636 mmol) gave a thick colourless oil; column 
chromatography (hexane/ethyl acetate, 10:1) gave compound (15b),  (62 mg, 71%); [α] 22D
+3.8 (c 0.31, CHCl3); δH (400 MHz, CDCl3): 7.35 – 7.27 (10H, m), 4.68 (1H, d, J 11.8 Hz), 
4.65 (1H, d, J 11.8 Hz), 4.55 (2H, br.s), 4.43 (1H, dd, J 4.1, 11.7 Hz), 4.22 (1H, dd, J 5.5, 
11.7 Hz), 3.86 – 3.80 (1H, m), 3.67 – 3.55 (3H, including br dd J 1.6, 5.4 Hz at δ 3.6), 2.45 
(1H, d, J 8.0 Hz), 2.43 (1H, br.dd, J 3.8, 10.5 Hz), 1.80 – 1.00 (134H, m), 0.89 (6H, t, J 6.7 
Hz), 0.71 – 0.61 (4H, m), 0.57 (2H, dt, J 3.9, 8.4 Hz), -0.32 (2H, br.q, J 5.2 Hz); δC (101 
MHz, CDCl3): 175.4, 138.0, 137.9, 128.4, 128.3, 127.8, 127.7, 127.6, 75.8, 73.5, 72.3, 72.1, 
69.6, 63.5, 51.4, 35.5, 31.9, 30.2, 29.7, 29.6, 29.5, 29.4, 29.3, 28.7, 27.5, 25.8, 23.0, 15.8, 
14.1, 10.9; νmax: 2991, 2917, 2850, 1732, 1599, 1469 cm-1. 
(b) Palladium hydroxide on activated charcoal (0.0077 g)  and ester (15b) (0.0515 g, 0.0369 
mmol) gave a thick colourless oil; column chromatography (chloroform /methanol, 10:1) 
gave the title compound (16b) (40 mg, 92%) [MALDI–Found (M+Na)+: 1234.2001, 
C81H158NaO5, requires: 1234.2007]; [α] 22D +1.8 (c 0.34, CHCl3); δH (400 MHz, CDCl3 + few 
drops of CD3OD): 4.21 (1H, dd, J 4.3, 11.4 Hz), 4.10 (1H, dd, J 6.4, 11.5 Hz), 3.89 – 3.80 
(1H, m), 3.60 (2H, br dd, J 4.1, 11.5 Hz), 3.54 (1H, dd, J 5.8, 11.6 Hz), 2.39 (1H, ddd, J 4.8, 
7.6, 10.0 Hz), 1.86 – 0.94 (137H, m), 0.84 (6H, t, J 6.8 Hz), 0.65 – 0.56 (4H, m), 0.52 (2H, 
dt, J 3.9, 8.5 Hz), -0.37 (2H, br.q, J 4.9 Hz); δC (101 MHz, CDCl3 + few drops of CD3OD): 
175.5, 72.6, 69.8, 65.1, 63.0, 52.5, 37.0, 35.0, 31.8, 30.1, 29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 
29.2, 28.6, 27.4, 25.3, 22.6, 15.7, 14.0, 10.8; νmax: 3585, 2917, 2849, 1734, 1468 cm-1. 
 
4.9 (S)-2,3-Dihydroxypropyl(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-
18-methylhexatriacontyl)cyclopropyl)octadecyl)tetracosanoate (16c) 
 (a) Cesium hydrogen carbonate (0.0436 g, 0.225 mmol), tosylate (14) (0.0211 g, 0.0495 
mmol) and  acid 11c (0.0552 g, 0.0450 mmol) [36] gave a thick colourless oil which was 
purified by column chromatography (hexane/ethyl acetate, 10:1) to afford compound (15c), 
(41 mg, 62%); [α] 22D +9.0 (c 0.31, CHCl3), which showed δH (400 MHz, CDCl3): 7.32 – 7.19 
(10H, m), 4.62 (1H, d, J 11.8 Hz), 4.58 (1H, d, J 11.8 Hz), 4.48 (2H, br s), 4.36 (1H, dd, J 
4.1, 11.7 Hz), 4.15 (1H, dd, J 5.5, 11.7 Hz), 3.81 – 3.72 (1H, m), 3.60 – 3.49 (3H, including 
br dd,  J 1.6, 5.4 Hz, at 3.53), 3.28 (3H, s), 2.90 (1H, br.p, J 4.1 Hz), 2.39 (1H, d, J 7.9 Hz), 
2.36 (1H, br.dd, J 3.5, 7.4 Hz), 1.75 – 0.93 (143H, m), 0.83 (6H, t, J 6.8 Hz), 0.79 (3H, d, J 
6.9 Hz), 0.65 – 0.54 (2H, m), 0.50 (1H, dt, J 4.0, 8.4 Hz), -0.39 (1H, br q, J 5.2 Hz); δC 
(101MHz, CDCl3): 175.3, 137.9, 137.8, 128.3, 128.2, 127.7, 127.6, 127.5, 85.3, 75.7, 73.4, 
72.2, 72.0, 69.5, 63.4, 57.6, 51.3, 38.6, 35.4, 35.2, 32.3, 31.8, 30.4, 30.3, 30.1, 29.9, 29.8, 
29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.8, 28.6, 27.5, 27.4, 26.0, 25.7, 23.6, 22.9, 22.6, 15.7, 
14.8, 14.0, 13.9, 10.9, 10.8; νmax: 2923, 2853, 1737, 1465 cm-1. 
(b) Palladium hydroxide on activated charcoal (0.0054 g) and ester (15c) (0.0364 g, 
0.0245mmol) gave a thick colourless oil; column chromatography (chloroform/methanol, 
20:1) gave the title compound (16c) (27 mg, 85%); [MALDI–Found (M+Na)+: 1322.2890, 
C86H170NaO6, requires: 1322.2895]; [α] 23D +1.6 (c 2.1, CHCl3); δH (400 MHz, CDCl3 + few 
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drops of CD3OD): 4.21 (1H, dd, J 4.3, 11.4 Hz), 4.11 (1H, dd, J 6.4, 11.4 Hz), 3.88 – 3.82 
(1H, m), 3.66 – 3.57 (2H, including br dd, J 4.3, 11.4 Hz at δ 3.6), 3.54 (1H, dd, J 5.8, 11.6 
Hz), 3.31 (3H, s), 2.94 (1H, br.p, J 4.4 Hz), 2.40 (1H, ddd, J 4.8, 7.4, 10.2 Hz), 1.81 – 0.94 
(146H, m), 0.84 (6H, t, J 7.0 Hz), 0.81 (3H, d, J 6.9 Hz), 0.65 – 0.57 (2H, m), 0.52 (1H, dt, J 
4.0, 8.5 Hz), -0.37 (1H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3 + few drops of CD3OD): 175.5, 
85.5, 72.6, 69.8, 65.1, 63.0, 57.6, 52.4, 35.3, 35.0, 32.3, 31.8, 30.4, 30.1, 29.9, 29.8, 29.7, 
29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 28.6, 27.5, 27.4, 26.0, 25.3, 22.6, 15.7, 14.7, 14.0, 10.8; 
νmax: 3368, 2918, 2850, 1731, 1467 cm-1. 
 
4.10 (S)-2,3-dihydroxypropyl (R)-2-((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-
eicosylcyclopropyl)tetradecyl)cyclopropyl)dodecyl)hexacosanoate (16e) 
(a) Cesium hydrogen carbonate (0.0605 g, 0.312 mmol), tosylate (14) (0.0293 g, 0.0687 
mmol) and acid 11e (0.0711 g, 0.0624 mmol) [33] gave a thick colourless oil which was 
purified by column chromatography (hexane/ethyl acetate, 10:1) to afford compound (15e) 
(51 mg, 58%); [α] 23D +3.6 (c 0.88, CHCl3); δH (400 MHz, CDCl3): 7.37 – 7.26 (10H, m), 4.68 
(1H, d, J 11.8 Hz), 4.65 (1H, d, J 11.9 Hz), 4.55 (2H, br.s), 4.43 (1H, dd, J 4.0, 11.7 Hz), 4.22 
(1H, dd, J 5.5, 11.7 Hz), 3.86 – 3.80 (1H, m), 3.67 – 3.56 (3H, including br dd J 1.6, 5.4 Hz 
at 3.60), 2.45 (1H, d, J 7.9 Hz), 2.43 (1H, br.dd, J 3.5, 7.4 Hz) 1.85 – 0.97 (134H, m), 0.89 
(6H, t, J 7.2 Hz), 0.70 – 0.61 (4H, m), 0.60 – 0.57 (2H, dt, J 4.0, 8.5 Hz), -0.32 (2H, br q, J 
5.2 Hz); δC (101 MHz, CDCl3): 175.4, 138.0, 137.8, 128.4, 128.3, 127.7, 127.6, 127.5, 121.9, 
75.7, 73.4, 72.3, 72.0, 69.5, 63.4, 51.3, 35.5, 31.9, 30.1, 29.7, 29.6, 29.5, 29.45, 29.4, 29.3, 
28.6, 27.4, 25.7, 22.6, 15.7, 14.0, 10.8; νmax: 3435, 2917, 2850, 1732, 1468 cm-1. 
(b) Palladium hydroxide on activated charcoal (0.0063g) and ester (15e) (0.0425g, 0.0305 
mmol) gave a thick oil; column chromatography (chloroform/methanol, 20:1) gave the title 
compound (16e) (27 mg, 74%) [MALDI–Found (M+Na)+: 1234.2001, C81H158NaO5, 
requires: 1234.2007]; [α] 23D +2.3 (c 5.2, CHCl3); δH (400 MHz, CDCl3 + few drops of 
CD3OD): 4.22 (1H, dd, J 4.4, 11.5 Hz), 4.12 (1H, dd, J 6.4, 11.5 Hz), 3.89 – 3.83 (1H, m), 
3.67 – 3.58 (2H, including br dd, J 4.0, 11.1 Hz at 3.61), 3.55 (1H, dd, J 5.8, 11.6 Hz), (1H, 
ddd, J 4.4, 7.9, 10.0 Hz), 1.79 – 0.96 (137H, m), 0.85 (6H, t, J 6.8 Hz), 0.66 – 0.57 (4H, m), 
0.53 (2H, dt, J 4.4, 8.4 Hz), -0.36 (2H, br.q, J 5.1 Hz); δC (126 MHz, CDCl3 + few drops of 
CD3OD): 175.4, 72.4, 69.6, 65.0, 62.8, 52.4, 31.7, 30.0, 29.4, 29.1, 29.0, 28.5, 27.2, 25.1, 
22.4, 15.5, 13.8, 10.6; νmax: 3400, 3017, 2917, 2850, 1733, 1468 cm-1. 
 
4.11 (S)-2,3-dihydroxypropyl (R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-
methoxy-18-methylhexatriacontyl)cyclopropyl)octadecyl)hexacosanoate (16f)  
(a) Cesium hydrogen carbonate (0.0351 g, 0.181 mmol), tosylate (14)  (0.0170 g, 0.0399 
mmol) and acid 11f (0.0455 g, 0.0362 mmol) [38]. A thick colourless oil residue which was 
purified by column chromatography (hexane/ethyl acetate, 10:1) to afford compound (15f) 
(40 mg, 72%); [α] 23D +6.4 (c 0.50, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.26 (10H, m), 4.70 
(1H, d, J 11.8 Hz), 4.66 (1H, d, J 11.8 Hz), 4.57 (2H, br.s), 4.44 (1H, dd, J 4.1, 11.6 Hz), 4.23 
(1H, dd, J 5.5, 11.7 Hz), 3.85 (1H, m), 3.69 – 3.57 (3H, including br dd,  J 1.6, 5.4 Hz at 
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3.62), 3.37 (3H, s), 2.98 (1H, br.p, J 3.8 Hz), 2.47 (1H, d, J 7.9 Hz), 2.44 (1H, br.dd, J 4.5, 
8.5 Hz), 1.88 – 1.03 (147H, m), 0.91 (6H, t, J 7.1 Hz), 0.89 (3H, d, J 6.8 Hz), 0.71 – 0.63 
(2H, m), 0.58 (1H, dt, J 4.0, 8.3 Hz), -0.31 (1H, br.q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.4, 
128.4, 128.3, 127.7, 127.6, 127.5, 85.3, 75.7, 73.4, 72.2, 72.0, 69.5, 68.0, 63.4, 57.6, 51.3, 
38.6, 35.4, 35.2, 32.3, 31.8, 30.4, 30.3, 30.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.8, 
28.6, 27.5, 27.4, 26.0, 22.6, 15.7, 14.8, 14.0, 10.8; νmax: 3030, 2923, 2853, 1733, 1496 cm-1. 
(b) Palladium hydroxide on activated charcoal (0.0032g) and ester (15f) (0.0215g, 0.0142 
mmol) gave a thick colourless oil; column chromatography (chloroform/methanol, 20:1) gave 
the title compound (16f) (18 mg, 92%) [MALDI–Found (M+Na)+: 1350.3203, C88H154NaO6, 
requires: 1350.3208]; [α] 23D +1.9 (c 0.74, CHCl3); δH (400 MHz, CDCl3 + few drops of 
CD3OD): 4.22 (1H, dd, J 4.2, 11.5 Hz), 4.12 (1H, dd, J 6.4, 11.5 Hz), 3.89 – 3.83 (1H, m), 
3.71 – 3.58 (2H, including br.dd, J 4.1, 11.5 Hz at δ 3.61), 3.55 (1H, dd, J 5.8, 11.5 Hz), 3.31 
(3H, s), 2.94 (1H, br.p, J 3.7 Hz), 2.40 (1H, ddd, J 4.8, 7.4, 10.4 Hz), 1.68 – 0.94 (150H, m), 
0.85 (6H, t, J 6.9 Hz), 0.82 (3H, d, J 6.9 Hz), 0.65 – 0.58 (2H, m), 0.52 (1H, dt, J 4.0, 8.1 
Hz), -0.37 (1H, br.q, J 5.2 Hz); δC (101 MHz, CDCl3 + few drops of CD3OD): 175.5, 85.5, 
72.6, 69.7, 65.1, 63.0, 58.0, 52.5, 35.2, 35.0, 33.0, 31.8, 30.4, 30.1, 29.8, 29.7, 29.6, 29.55, 
29.5, 29.4, 29.3, 29.2, 29.1, 28.6, 27.4, 27.3, 26.0, 25.3, 22.6, 15.7, 14.7, 14.0, 10.8;  νmax: 
3389, 3017, 2919, 2850, 1733, 1467 cm-1. 
 
4.12 (S)-2,3-dihydroxypropyl(2R)-2-((1R)-1-hydroxy-16-((1R,2S)-2-(20-methyl-19-oxo-
octatriacontyl)cyclopropyl)hexadecyl)hexacosanoate (16g) 
(a) Cesium hydrogen carbonate (0.0572 g, 0.295 mmol), tosylate (14)  (0.0277 g, 0.0649 
mmol) and  acid 11g (0.0731 g, 0.0590 mmol) [35] gave a thick colourless oil which was 
purified by column chromatography (hexane/ethyl acetate, 10:1) to afford compound (15g), 
(52 mg, 59%); [α] 23D +6.5 (c 0.55, CHCl3); δH (400 MHz, CDCl3): 7.31 – 7.05 (10H, m), 4.60 
(1H, d, J 11.8 Hz), 4.57 (1H, d, J 11.8 Hz), 4.47 (2H, br.s), 4.35 (1H, dd, J 4.0, 11.7 Hz), 4.14 
(1H, dd, J 5.5, 11.7 Hz), 3.80 – 3.71 (1H, m), 3.58 – 3.48 (3H, including br dd,  J 1.4, 5.4 Hz 
at 3.52), 2.48 – 2.38 (2H, including OH proton at 2.43), 2.38 – 2.29 (3H, including dt,  J 5.4, 
7.9 Hz, at 2.35), 1.75 – 1.01 (144H, m), 0.98 (3H, d, J 6.9 Hz), 0.81 (6H, t, J 6.7 Hz), 0.62 – 
0.53 (2H, m), 0.49 (1H, dt, J 4.0, 8.5 Hz), -0.40 (1H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 
215.0, 175.7, 138.0, 128.4, 128.3, 127.7, 127.6, 127.5, 75.7, 73.4, 72.2, 72.0, 69.5, 63.4, 51.3, 
46.2, 41.0, 35.4, 33.0, 31.8, 30.1, 29.6, 29.55, 29.5, 29.4, 29.35, 29.3, 29.2, 28.6, 27.4, 27.2, 
25.7, 23.7, 23.6, 22.6, 16.3, 15.7, 14.0, 10.8; νmax: 2918, 2850, 1717, 1467 cm-1. 
(b) As above, using palladium hydroxide on activated charcoal (0.0075 g) and ester (15g) 
(0.0505 g), eluting with chloroform/methanol (40:1) gave the title compound (16g) (38 mg, 
87%) [MALDI–Found (M+Na)+: 1334.2890, C87H170NaO6, requires: 1334.2895]; [α] 23D +2.8 
(c 3.6, CHCl3), which showed δH (400 MHz, CDCl3 + few drops of CD3OD): 4.22 (1H, dd, J 
4.2, 11.4 Hz), 4.11 (1H, dd, J 6.5, 11.4 Hz), 3.89 – 3.81 (1H, m), 3.68 – 3.57 (2H, including 
br dd J 4.3, 11.5 Hz at δ 3.61), 3.54 (1H, dd, J 5.8, 11.6 Hz), 2.53 – 2.44 (1H, m), 2.38 (3H, 
including br.t, J 2.38), 1.68 – 1.05 (147H, m), 1.01 (3H, d, J 6.9 Hz), 0.84 (6H, t, J 6.7 Hz), 
0.65 – 0.57 (2H, m), 0.52 (1H, dt, J 4.1, 8.4 Hz), -0.37 (1H, br q, J 5.2 Hz); δC (126 MHz, 
CDCl3 + few drops of CD3OD): 216.0, 175.5, 72.6, 69.7, 65.1, 63.0, 52.5, 46.3, 41.1, 35.0, 
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32.9, 31.8, 30.1, 29.7, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 29.25, 29.2, 29.15, 29.1, 
28.6, 27.4, 27.2, 25.3, 23.6, 22.6, 16.2, 15.7, 14.0, 10.8; νmax: 3396, 3017, 2922, 2853, 1713, 
1467 cm-1. 
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 Highlights: 
Nine examples of R- and S-glycerol mycolates (GroMMs) based on synthetic 
mycolic acids matching the overall structures of alpha-, keto- and methoxy-
mycolic acids of Mycobacterium tuberculosis and other mycobacteria. 
 
